Labelling under Sections 21 to 23 and Bilingual Labelling
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Canadian labelling obligations operate in three layers. Section 21(1) lists 10 items of mandatory content: the device name; the manufacturer’s name and address; the device identifier; the control number for Class III and IV devices; the contents of the package; the word Sterile where applicable; the expiry date; the intended uses and the performance specifications needed for correct use; the instructions for use; and any special storage conditions. Section 23(1) requires that this information be provided at minimum in English or in French. Section 23(3) then provides that for devices sold to the general public, the information in paragraphs 21(1)(a) and (e) to (j) must be provided in both English and French. Reading the three layers together, rather than stopping at the bilingual headline, is what produces an accurate labelling plan and an accurate language budget.
- Section 21(1) prescribes 10 mandatory label content items.
- Section 21(2) requires the information to be clear, legible and prominent, in terms understandable to the intended user.
- Section 23(1): minimum English or French for all devices.
- Section 23(2): the other official language’s instructions for use must be supplied on request without delay.
- Section 23(3): devices sold to the general public require both English and French for paragraphs 21(1)(a) and (e) to (j).
- Sections 21.1 and 21.2: relabelling of non-compliant imported devices within 3 months.
2. Legal basis
The table below lists the provisions of the Medical Devices Regulations relied on in this article, including the amendments that introduced the import relabelling mechanism. All provisions were verified against Justice Laws.
| Medical Devices Regulations | Sections 21(1)(a) to (j): the 10 items of label content | SOR/98-282 (as amended by SOR/2002-190 and SOR/2015-193) | Justice Laws |
| Medical Devices Regulations | Section 21(2): the information must be clear, legible and prominent and expressed in terms understandable to the intended user | same | Justice Laws |
| Medical Devices Regulations | Section 22: outer packaging requirements for devices sold to the general public; where packaging is too small, the information is supplied in accompanying instructions | same | Justice Laws |
| Medical Devices Regulations | Section 23(1): minimum English or French; section 23(2): the other official language’s instructions to be provided on the purchaser’s request without delay; section 23(3): devices sold to the general public require English and French (paragraphs 21(1)(a) and (e) to (j)) | same | Justice Laws |
| Medical Devices Regulations | Sections 21.1 and 21.2: advance notification before importing non-compliant labelled devices and relabelling within 3 months | amended by SOR/2018-225 | Justice Laws |
3. Expert insights
Insight 1: the boundary of the bilingual obligation is whether the device is sold to the general public, not whether it is sold in Canada.
This is the most frequent misreading of the Canadian labelling rules. Under section 23(1), a device not sold to the general public must carry its information in either English or French; under section 23(3), a device sold to the general public must carry paragraphs 21(1)(a) and (e) to (j) in both English and French. Writing the rule as a blanket statement that Canada requires bilingual labelling overstates the compliance cost for professional-use devices substantially, and writing it as single-language-for-everything understates it for consumer devices. The determination of public-sale status should therefore be made deliberately, product by product, documented in the labelling plan, and allowed to drive the language scheme rather than a general assumption about the Canadian market.
Insight 2: the supply-on-request obligation of section 23(2) is a third layer.
Under section 23(2), where instructions for use are supplied in only one official language at the time of sale, the manufacturer must supply the instructions in the other official language without delay on the purchaser’s request. This means that even for devices not sold to the general public, the manufacturer must be able to produce the other language version when asked. The obligation is conditional, but the capability behind it cannot be conjured on demand: the other-language version must exist or be producible quickly. Compliance planning should therefore include the other official language version in the documentation set — maintained, versioned and ready for release — even where the routine labelling is single-language, so that a purchaser’s request does not become a translation emergency.
Insight 3: the control number of section 21(1)(d) applies only to Class III and IV.
Under section 21(1)(d), the control number is required only in the case of a Class III or Class IV device. Class I and Class II devices do not fall under this item. The point matters in two directions. For Class III and IV projects, the control number must appear on the label and its generation and traceability should be part of the production control system, since the number is the hook that links a specific unit to its manufacturing records. For Class I and II projects, including the control number is optional rather than required, and the labelling checklist should not demand it as a compliance item where the class does not call for it. Matching the checklist to the class avoids both a missing mandatory item and an unnecessary burden.
Insight 4: importing devices with non-compliant labels has a dedicated channel, but the deadline is 3 months.
Under section 21.1, where a device that is not labelled in accordance with the Regulations is imported for sale, the import may proceed on two conditions: first, the licensed importer or manufacturer must notify the Minister before the import; second, the manufacturer must relabel the device in accordance with the Regulations within 3 months of the day of import and before sale. Under section 21.2, the manufacturer must also ensure the Minister is notified in writing of the name of the person who will relabel the device in Canada. The channel is useful where stock is labelled for another market, but the 3-month clock starts at import, not at the moment the relabelling project is staffed. Treating the deadline as a hard milestone — with the relabelling site, capacity and materials arranged before the goods ship — is the only way the channel works as intended.
4. Practical recommendations
- Use the 10 items of section 21(1) as a line-by-line checklist; no item may be missing.
- Determine public-sale status first, then set the language scheme: if yes, English and French bilingual; if no, English or French plus the other official language version ready to supply on request.
- Add the control number for Class III and IV devices (section 21(1)(d)).
- For devices sold to the general public, place the information on the outer packaging and make it visible under normal conditions of sale under section 22; where packaging is too small, supply it in accompanying instructions.
- Where the section 21.1 channel is used, make the 3-month relabelling deadline a hard milestone.
5. Verification checklist
- □ The label has been checked item by item against the 10 items of section 21(1).
- □ Public-sale status has been determined and the language scheme follows from it.
- □ The control number is present for Class III and IV devices.
- □ Public-facing devices meet the outer packaging and visibility requirements of section 22.
- □ For non-public devices, the other official language instructions for use are ready to supply on request (section 23(2)).
- □ Where the section 21.1 channel is used, the 3-month relabelling deadline is set as a hard milestone.
Regulatory information verified as of October 28, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us